Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.53 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 4/20 | 0.53 |
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 3/20 | 0.50 |
| ▸ | FNTB | P49356 | 3/20 | 0.50 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609991 | 1.00 | NPY1R (0.53) | NPY1RNPY2RNPY4RMMEACE | |
| SCHEMBL29558363 | 0.93 | ENPEP (0.52) | NPY1RNPY2RNPY4RMMEACE | |
| SCHEMBL30311095 | 0.91 | ENPEP (0.57) | NPY1RNPY2RNPY4RNAALAD2FNTA | |
| SCHEMBL29794193 | 0.90 | FNTA (0.55) | FNTAFNTBPGGT1B | |
| SCHEMBL21828645 | 0.90 | FNTA (0.55) | FNTAFNTBPGGT1B | |
| SCHEMBL2549632 | 0.90 | FNTA (0.55) | FNTAFNTBPGGT1B | |
| SCHEMBL26417444 | 0.90 | NPY4R (0.53) | NPY1RNPY2RNPY4RACE | |
| SCHEMBL13154780 | 0.90 | FNTA (0.60) | MMEFNTAFNTBPGGT1B | |
| SCHEMBL9442969 | 0.90 | FNTA (0.60) | MMEFNTAFNTBPGGT1B | |
| SCHEMBL10696437 | 0.90 | FNTA (0.60) | MMEFNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | claimed |
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024235082-A1 | USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS | 海口桥水联合科技有限责任公司 | 2024-11-21 | — | — | WO | claimed |
| CN-116350746-B | Application of sardine peptide composition in medicines for treating allergic rhinitis | 海口桥水联合科技有限责任公司 | 2024-03-22 | — | — | CN | claimed |
| WO-2023212662-A2 | COMPOSITIONS AND METHODS FOR MODULATING ANTIGEN BINDING ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230340416-A1 | AUGMENTATION OF FIBROBLAST THERAPEUTIC ACTIVITY BY COMPLEMENT BLOCKADE AND/OR INHIBITION | FIGENE, LLC | 2023-10-26 | — | — | US | claimed |
| CN-116350746-A | Application of sardine peptide composition in medicines for treating allergic rhinitis | 海口桥水联合科技有限责任公司 | 2023-06-30 | — | — | CN | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| US-20220395540-A1 | TREATMENT OF COVID-19 LUNG INJURY USING UMBILICAL CORD PLASMA BASED COMPOSITIONS | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2022-12-15 | — | — | US | claimed |
| CN-116375796-B | Anti-inflammatory peptide derived from pearl oyster and application thereof | SOUTH CHINA AGRICULTURAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12618845-B2 | Methods and compositions for protein sequencing | Quantum-Si Incorporated (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| WO-2025243299-A1 | NUTRIENT-BASED FORMULATIONS USABLE IN TREATING MUSCLE ATROPHY | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-11-27 | — | — | WO | disclosed |
| US-20250352544-A1 | TREATMENT OF MUSCLE ATROPHY USING GSK-3 INHIBITORS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-11-20 | — | — | US | disclosed |
| EP-0383472-B1 | Insulin analogs | LILLY CO ELI (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0678522-A1 | Insulin analogs | ELI LILLY AND COMPANY (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0383472-A2 | Insulin analogs | ELI LILLY AND COMPANY (US) | 1990-08-22 | — | — | EP | disclosed |
| EP-0127108-B1 | PROCESS FOR PREPARING POLYPEPTIDES | MERCK & CO. INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| US-4510083-A | POTASSIUM, CESIUM OR RUBIDIUM CARBONATE BUFFER FOR COUPLING OF AMINO ACID N-CARBOXYANHYDRIDE WITH ANOTHER AMINO ACID OR PEPTIDE | MERCK & CO., INC. (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0127108-A1 | Process for preparing polypeptides | MERCK & CO. INC. (US) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | NPY1R 625/4885NPY2R 784/4885NPY4R 1324/4885 |
| US-12618845-B2 | Methods and compositions for protein sequencing | PTMS, MICA, MAX | NPY1R 1140/4885NPY2R 1789/4885NPY4R 1927/4885 |
| US-20250352544-A1 | TREATMENT OF MUSCLE ATROPHY USING GSK-3 INHIBITORS | GSK3B, GSK3A, PYGM | NPY1R 3525/4885NPY2R 3693/4885NPY4R 3094/4885 |
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | VIP, ANPEP, RNPEP | NPY1R 438/4885NPY2R 343/4885NPY4R 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.